BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37086780)

  • 1. Impact of prior cryptococcal antigen screening on in-hospital mortality in cryptococcal meningitis or fungaemia among HIV-seropositive individuals in South Africa: a cross-sectional observational study.
    Paccoud O; Shuping L; Mashau R; Greene G; Quan V; Meiring S; Govender NP;
    Clin Microbiol Infect; 2023 Aug; 29(8):1063-1069. PubMed ID: 37086780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of screening and treatment of cryptococcal antigenaemia among HIV-infected persons in Soweto, South Africa.
    Govender NP; Roy M; Mendes JF; Zulu TG; Chiller TM; Karstaedt AS
    HIV Med; 2015 Sep; 16(8):468-76. PubMed ID: 25689352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevalence of cryptococcal antigen (CrAg) and benefits of pre-emptive antifungal treatment among HIV-infected persons with CD4+ T-cell counts < 200 cells/μL: evidence based on a meta-analysis.
    Li Y; Huang X; Chen H; Qin Y; Hou J; Li A; Wu H; Yan X; Chen Y
    BMC Infect Dis; 2020 Jun; 20(1):410. PubMed ID: 32532212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cryptococcal antigenemia is associated with meningitis or death in HIV-infected adults with CD4 100-200 cells/mm
    Wykowski J; Galagan SR; Govere S; Wallis CL; Moosa MY; Celum C; Drain PK
    BMC Infect Dis; 2020 Jan; 20(1):61. PubMed ID: 31959112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory-Reflex Cryptococcal Antigen Screening Is Associated With a Survival Benefit in Tanzania.
    Faini D; Kalinjuma AV; Katende A; Mbwaji G; Mnzava D; Nyuri A; Glass TR; Furrer H; Hatz C; Boulware DR; Letang E
    J Acquir Immune Defic Syndr; 2019 Feb; 80(2):205-213. PubMed ID: 30422904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory Reflex and Clinic-Based Point-of-Care Cryptococcal Antigen Screening for Preventing Meningitis and Mortality Among People Living With HIV.
    Drain PK; Galagan SR; Govere S; Krows M; Thulare H; Wallis CL; Gosnell BI; Moosa MY; Celum C; Bassett IV
    J Acquir Immune Defic Syndr; 2021 Aug; 87(5):1205-1213. PubMed ID: 33990495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and mortality of cryptococcal disease in adults with advanced HIV in an urban tertiary hospital in Sierra Leone: a prospective study.
    Lakoh S; Rickman H; Sesay M; Kenneh S; Burke R; Baldeh M; Jiba DF; Tejan YS; Boyle S; Koroma C; Deen GF; Beynon F
    BMC Infect Dis; 2020 Feb; 20(1):141. PubMed ID: 32059703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a national cryptococcal antigen screening program for HIV-infected patients in Uganda: A cost-effectiveness modeling analysis.
    Rajasingham R; Meya DB; Greene GS; Jordan A; Nakawuka M; Chiller TM; Boulware DR; Larson BA
    PLoS One; 2019; 14(1):e0210105. PubMed ID: 30629619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cryptococcal antigen prevalence in HIV-infected Tanzanians: a cross-sectional study and evaluation of a point-of-care lateral flow assay.
    Rugemalila J; Maro VP; Kapanda G; Ndaro AJ; Jarvis JN
    Trop Med Int Health; 2013 Sep; 18(9):1075-1079. PubMed ID: 23937699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryptococcal-related Mortality Despite Fluconazole Preemptive Treatment in a Cryptococcal Antigen Screen-and-Treat Program.
    Wake RM; Govender NP; Omar T; Nel C; Mazanderani AH; Karat AS; Ismail NA; Tiemessen CT; Jarvis JN; Harrison TS
    Clin Infect Dis; 2020 Apr; 70(8):1683-1690. PubMed ID: 31179488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cryptococcal antigen positivity combined with the percentage of HIV-seropositive samples with CD4 counts <100 cells/μl identifies districts in South Africa with advanced burden of disease.
    Coetzee LM; Cassim N; Sriruttan C; Mhlanga M; Govender NP; Glencross DK
    PLoS One; 2018; 13(6):e0198993. PubMed ID: 29894509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymptomatic cryptococcal antigen prevalence detected by lateral flow assay in hospitalised HIV-infected patients in São Paulo, Brazil.
    Vidal JE; Toniolo C; Paulino A; Colombo A; Dos Anjos Martins M; da Silva Meira C; Pereira-Chioccola VL; Figueiredo-Mello C; Barros T; Duarte J; Fonseca F; Alves Cunha M; Mendes C; Ribero T; Dos Santos Lazera M; Rajasingham R; Boulware DR
    Trop Med Int Health; 2016 Dec; 21(12):1539-1544. PubMed ID: 27699970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study.
    Longley N; Jarvis JN; Meintjes G; Boulle A; Cross A; Kelly N; Govender NP; Bekker LG; Wood R; Harrison TS
    Clin Infect Dis; 2016 Mar; 62(5):581-587. PubMed ID: 26565007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outpatient Cryptococcal Antigen Screening Is Associated With Favorable Baseline Characteristics and Improved Survival in Persons With Cryptococcal Meningitis in Uganda.
    Levin AE; Bangdiwala AS; Nalintya E; Kagimu E; Kasibante J; Rutakingirwa MK; Mpoza E; Jjunju S; Nuwagira E; Naluyima R; Kirumira P; Hou C; Ssebambulidde K; Musubire AK; Williams DA; Abassi M; Muzoora C; Hullsiek KH; Rajasingham R; Meya DB; Boulware DR; Skipper CP
    Clin Infect Dis; 2023 Feb; 76(3):e759-e765. PubMed ID: 35859045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Cryptococcal Antigen Titers in Blood Are Predictive of Subclinical Cryptococcal Meningitis Among Human Immunodeficiency Virus-Infected Patients.
    Wake RM; Britz E; Sriruttan C; Rukasha I; Omar T; Spencer DC; Nel JS; Mashamaite S; Adelekan A; Chiller TM; Jarvis JN; Harrison TS; Govender NP
    Clin Infect Dis; 2018 Feb; 66(5):686-692. PubMed ID: 29028998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence, correlates, and outcomes of cryptococcal antigen positivity among patients with AIDS, United States, 1986-2012.
    McKenney J; Bauman S; Neary B; Detels R; French A; Margolick J; Doherty B; Klausner JD
    Clin Infect Dis; 2015 Mar; 60(6):959-65. PubMed ID: 25422390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa.
    Jarvis JN; Harrison TS; Lawn SD; Meintjes G; Wood R; Cleary S
    PLoS One; 2013; 8(7):e69288. PubMed ID: 23894442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of Reflex Cryptococcal Antigen (CrAg) Screening in Human Immunodeficiency Virus (HIV)-Positive Patients With CD4 Counts of 100-200 Cells/µL in Botswana.
    Tenforde MW; Milton T; Rulaganyang I; Muthoga C; Tawe L; Chiller T; Greene G; Jordan A; Williams CG; Owen L; Leeme TB; Boose A; Ngidi J; Mine M; Jarvis JN
    Clin Infect Dis; 2021 May; 72(9):1635-1638. PubMed ID: 32604411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cryptococcal infection in HIV-infected patients with CD4
    Pérez-Jacoiste Asín MA; Bisbal O; Iribarren JA; Pérez-Rivilla A; Mican R; Dronda F; González-Domenech CM; Vinuesa-García D; Macías J; Lumbreras C; Moreno S; Rubio R;
    Clin Microbiol Infect; 2021 Aug; 27(8):1171.e1-1171.e7. PubMed ID: 33069858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishing a cost-per-result of laboratory-based, reflex Cryptococcal antigenaemia screening (CrAg) in HIV+ patients with CD4 counts less than 100 cells/μl using a Lateral Flow Assay (LFA) at a typical busy CD4 laboratory in South Africa.
    Cassim N; Schnippel K; Coetzee LM; Glencross DK
    PLoS One; 2017; 12(2):e0171675. PubMed ID: 28166254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.